

AI Assistant in Brain Tumor Prediction: A Comprehensive Review of Techniques, Trends, and Future Prospects

Aparna Sharma¹, Saurav Kumar Jha², Rajesh Kumar³

Assistant Professor, Department of CSA, Sharda University Greater Noida, UP, India
Email: [aparnaa.mca\[at\]gmail.com](mailto:aparnaa.mca[at]gmail.com)

Student MCA, Department of CSA, Sharda University Greater Noida UP, India

Student MCA, Department of CSA, Sharda University Greater Noida UP, India
Email: [2023487457.rajesh\[at\]pg.sharda.ac.in](mailto:2023487457.rajesh[at]pg.sharda.ac.in)

Abstract: AI (Artificial Intelligence) is transforming medical imaging, especially regarding the early and precise identification of brain tumors like gliomas, meningiomas, and pituitary adenomas. AI (Artificial Intelligence) is transforming medical imaging, especially regarding the early and precise identification of brain tumors like gliomas, meningiomas, and pituitary adenomas. Special attention is given to convolutional neural networks (CNNs), which are commonly used due to their capability of capturing spatial and hierarchical features from MRI scans. Architectures like U-Net, ResNet, and DenseNet, as well as hybrid models, are examined for their efficacy in tumor classification and segmentation. Algorithm selection, clinical applicability, and dataset considerations are also discussed in the review. This paper delineates the changing function of AI assistants in brain tumor prediction and the prospective trajectory of AI-driven diagnostic processes in clinical environments by integrating contemporary trends and developments.

Keywords: AI Assistant, Brain Tumor Prediction, MRI, Deep, Deep Learning, CNN, Medical Imaging, Machine Learning, Healthcare AI

1. Introduction

Brain tumors are a large class of neurological disorders, defined by abnormal cell growth in the brain or surrounding tissues. These tumors may be benign or malignant, and malignant types can often be life-threatening due to their aggressive growth and ability to inhibit fundamental brain functions. There are many different tumor types and human brain anatomy is complex, making accurate diagnosis challenging, particularly when early diagnosis is important to improving patient health outcomes. Traditional diagnostic methods involve imaging modalities and radiologists who visually interpret scans, like Magnetic Resonance Imaging (MRI). This method is only effective with trained professionals using interpretation methods but is subject to human error, diagnostic timelines, as well as inter-observer variability in limited resource settings. With an increasing number of images comes an increasing desire for better and more reliable diagnostic tools.



1.1 AI-Brain-Cancer-Tumor-Art-Concept

New developments in artificial intelligence (AI) especially with machine learning (ML) and deep learning (DL) are

profoundly changing medical imaging and diagnosis. Brain tumors can now be detected and classified and examined with assistance of AI (in some cases fully automated as well) allowing for faster, more accurate, and reproducible results. AI systems utilize large annotated datasets and nonlinear algorithms to identify human interpretable patterns in images. These technologies can detect anomalies that might be impossible to detect with human interpretable processes.

Contextualizing algorithms, datasets, tools, and techniques toward improved diagnostic accuracy, this study investigated the role of AI assistants in diagnosing brain tumors and attempts to analyze the obstacles and future directions in this rapidly changing field while providing some context to understand why AI technologies will fundamentally change detection of brain tumors.

1.1 Background

Gliomas, meningiomas, and pituitary tumors are examples of tumors of the brain, which present complexities in regards to their diagnosis, classification, treatment, and management, and to complicate matters further, every tumor has differences in tumor type, location and behavior. Clinicians feel it necessary to characterize and identify tumor type so they can plan clinical treatment and therefore improve patient outcomes.

Magnetic resonance imaging (MRI) has become the preferred method of imaging for brain tumors as it offers non-invasive views of soft tissue, is able to image in multiple planes, and has a good contrast resolution.

Even so, MRI interpretations still rely on radiologists to

Volume 14 Issue 5, May 2025

Fully Refereed | Open Access | Double Blind Peer Reviewed Journal

www.ijsr.net

manually interpret every MRI scan. This may not only be accurate but time consuming, and often workers miss the subtleties of small lesions or fail to identify abnormalities in early developments of a tumor. While high-quality image and diagnostic procedures are benefitting from, and attracting interest in convolutional neural networks (CNN) and artificial intelligence (AI) have shaken up the diagnostics in the medical imaging field in recent years, the extraction, segmentation, and classification of brain tumors from MRI images using CNN is very appealing as they understand spatial hierarchies of information and are power reliance on image data. Furthermore, large datasets can be consumed by these algorithms for comparison with then analyze patterns and features that a human may miss or not have in their

cognitive ability to analyze.


1.2 AI Assistant Integration in Neurodiagnostic

The incorporation of AI assistants as part of neurodiagnostic workflows represents a conceptual shift with respect to how brain-related disorders—such as tumors—are identified and treated. Neurodiagnostic have traditionally relied on neurological assessments, neuroimaging, and clinical history to render diagnoses. While this sequence of actions is accepted, it can be unwieldy and be reliant on expert interpretation which may differ from practitioner to practitioner.

Table 1: AI Assistant Integration in Neurodiagnostics

No.	AI Component	Diagnostic Function	Clinical/Operational Impact	Key Source
1	CNN-based Imaging Analysis	Extracts spatial and morphological tumor features from MRIs	Improves diagnostic accuracy, reduces inter-observer variability	Menze et al., 2015 (BraTS Challenge)
2	Radiomic Feature Extraction	Quantifies tumor texture, shape, and intensity	Enables tumor classification, grade prediction, and phenotypic profiling	Aerts et al., 2014
3	NLP-based EHR Assistants	Summarizes and flags critical patient data in clinical notes	Aids in clinical decision-making, reduces cognitive load on physicians	Vaswani et al., 2017 (Transformer model)
4	Prognostic Modeling	Predicts survival time, recurrence risk, and progression	Supports personalized treatment plans and outcome prediction	Bakas et al., 2018
5	Federated Learning Models	Trains models on distributed hospital datasets without data sharing	Preserves data privacy, enhances generalizability across institutions	Sheller et al., 2020
6	Transformer-based Multimodal Models	Integrates MRI, genomic, and clinical data	Enhances holistic understanding and personalized care recommendations	Huang et al., 2021
7	GANs for Synthetic MRI Generation	Generates realistic synthetic brain MRIs for training	Augments datasets, balances class distributions, improves model robustness	Shin et al., 2018
8	Explainable AI (XAI) Tools	Visualizes decision-making (e.g., heatmaps, saliency maps)	Builds clinician trust, aids in regulatory compliance	Lundberg & Lee, 2017 (SHAP); Selvaraju et al., 2017 (Grad-CAM)
9	3D Tumor Segmentation Networks	Performs volumetric segmentation using U-Net, nnU-Net, DeepMedic	Automates and speeds up tumor delineation for surgery and radiotherapy	Isensee et al., 2021
10	Clinical Decision Support Systems	Integrates AI predictions into hospital workflows	Facilitates early detection, surgical planning, and treatment decisions	Esteva et al., 2019

AI assistants have shown capability in processing complex imaging data, particularly MRI and CT scans, especially those based on deep learning architectures.



1.2 AI Assistant Integration in Neurodiagnostics

They can identify tumors, measure their size, classify tumor types, and measure their growth. In fact, for patients with rare or unusual tumor appearance, AI models may even offer some level of diagnostic criteria by generalizing the knowledge from large annotated datasets.

AI can be integrated into PACS (Picture Archiving and Communication Systems) and CDSS (Clinical Decision


Support Systems) to allow real-time analysis of neuroimaging data as it arrives at the hospital. Besides just helping with patient triage in terms of urgency, AI can help generate differential diagnoses, and draw attention to urgent issues needing an immediate assessment. AI neurodiagnostic platforms can be integrated with EHRs (Electronic Health Records) to further enhance the individualized, holistic approach to treatment by integrating imaging data with genomic characteristics, lab results, and patient histories.

1.3 Role of AI Assistant in Brain Tumor Prediction in Medical Imaging

AI (artificial intelligence) assistants are transforming medical imaging by enhancing radiologists' and clinicians' capacity for detection, analysis, and interpretation of complicated patterns in neuroimaging datasets. AI uses machine learning (ML) and deep learning (DL) algorithms that apply on a colossal number of labelled imaging datasets to allow the assistant to identify minute abnormalities that would be impossible to catch when manual reviewing.

The imaging workflow for brain tumor prediction consists of multiple stages, and AI assistants play an important role in each of them:

- **Pre-processing and enhancement of Imaging** - Sometimes considered a pre-step when producing MR Is, AI assistants that enhance imaging can reduce noise, remove artifacts, enhance the contrast and improve perceived quality, thus making it easier for a clinician to see the relevant structures in the brain.
- **Tumor Segmentation:** AI precisely defines tumor borders using convolutional neural networks (CNNs) and other deep learning methods, supporting treatment planning and volume estimation.



Graph: Role of AI Assistant in Brain Tumor Prediction Tasks

1.4 AI Assistant's Significance in Brain tumor prediction

Brain tumors are among the most complicated and hazardous conditions encountered in medicine today. There are some benign and more malignant (cancerous) types of brain tumors that are classified by abnormal cell growth in the brain or around the brain. The success of identifying treatment plans and improving patient outcomes relies on the timely identification and accurate classification of brain tumors. Although traditional diagnostic approaches constitute essential techniques for brain tumor diagnosis, the methods are often limited due to a lack of qualified radiologists, the subjective nature of interpretation, and the length of time it takes to interpret diagnostic information from MRI scans.

Over the last few years, artificial intelligence (AI) has transformed medical imaging by providing powerful means of augmenting human intelligence through the use of AI assistants in brain tumor diagnosis and treatment. AI systems have the capability of detecting small deviations, increasing the speed of identifying diagnoses, and generating high accuracy assessments that can assist in making clinical decisions as they are employing sophisticated algorithms that are leverage large datasets. This section outlines the variations in which AI aides assist in diagnosing and predicting brain tumors.

1.4.1 Early Detection and Diagnosis

Early diagnosis is the most critical factor in brain tumor management, but the broad range of symptoms produced by a brain tumor can often be masked or confused by other less serious illnesses, leading to a divergence or delay in diagnosis. Neuroimaging is the historical basis for the identification of structural lesions, primarily using Magnetic Resonance Imaging (MRI), and takes a long time to interpret manually with potential human error.

AI, particularly through deep learning models like Convolutional Neural Networks (CNNs) has been found quite effective for the early detection of tumors. These models analyze image data for patterns that human observers may not recognize as changes. AI methods provide automation and consistency to lower the chances of missed diagnoses, ultimately allowing patients to be identified and treated sooner.

1.4.2 Tumor Segmentation

Segmentation is the process of identifying the tumor boundaries in medical images, used to quantify the size, volume, and growth of tumors. Manual segmentation is time consuming and the measures taken by patients will differ by radiologist. AI approaches depend on classification algorithms, which allow them to allocate tumors on an image at the pixel level, quickly and accurately.

To deliver this task, state-of-the-art models like U-Net, ResNet, and 3D CNNs have been adapted. Along with being more consistent, these AI segmentations approaches are generalizable to other brain tumor types and image modalities. This would be beneficial for surgical navigation, therapeutics planning, and measuring for tumor progression or therapeutic responses.

1.4.3 Classification of Tumor Types

Once a tumor is detected, the next step is to determine the type of tumor for treatment and prognosis. The tumor behaviors and treatment tolerance of pituitary adenomas compared with meningiomas and gliomas are very different; this classification is something that could be supplemented by AI assistants that could take features (like texture, shape, and intensity) sort through and process these features to help classify the tumors.

There are AI classifiers with some supervised machine learning approaches (Support Vector Machines); Random Forests; and deep learning systems, that can distinguish one tumor from another very accurately. AI will never substitute a pathologist or oncologist, but add to and assist to establish that biopsy conference, after the biopsy is assessed, and assist in predicting, if prognosis and therapy needs are standardized there will be a reduction of wait time associated with diagnostic time turn-around time.

1.4.4 Treatment Planning

Personalized treatment planning is another example of how AI aides are becoming increasingly valuable. By incorporating imaging data with Electronic Health Records (EHRs), AI systems can suggest treatment plans based on patient profiles. These suggestions may encompass chemotherapy, radiation, and surgery based on patient medical history and tumor characteristics.

AI systems can also use historical patients' data to estimate treatment side effects, surgical risks, and long-term outcomes. The result is the enhancement of clinician-patient shared healthcare decision-making processes via predictive modeling, and, thus, more efficient and individualized treatment.

1.4.5 Prognosis and Survival Prediction


Aside from diagnosis and treatment, AI aides can affect

prognostic modeling. AI aides can evaluate clinical and imaging information to predict patient survival time, tumor recurrence, and the risk of metastasis. AI models can simultaneously consider a lot of variables, but derive their information from historic data, whereas the full affect regarding the trajectory of illnesses would be hard to recognize unaided.

The prognostic capability of AI aides can help to create effective follow-up plans and plans for long term care. Accurate prognosis permits the patient and family to prepare psychologically and make the best plans for their future.

1.4.6 Workflow Efficiency and Clinical Integration

AI assistants improve healthcare workflow performance, and diagnostic reliability. AI can reallocate aspects of the workflow that radiologists and physicians need to reallocate to AI techniques to fill the role for repetitive tasks including image preparation, abnormality detection, and report writing. This efficiency can be invaluable in areas with limited access to specialists or with healthcare situations with a large patient population. In support of real-time efficiency and analysis, hospitals also use AI with PACS (Picture Archiving and Communication Systems) and CDSS (Clinical Decision Support Systems), which are designed to assist physicians in timely decision-making upon patient presentation. AI can also configure or prioritize urgent cases to allow patients access to care when appropriate and required.



2. Literature Review

Within medicine, artificial intelligence (AI), and its most prevalent subcategory of deep learning (DL) have shown to have the most influence in the realm of medical imaging, including localization and classification of brain cancers. Teams of researchers have built models like BraTS (Brain Tumor Segmentation Challenge) and TCIA, all producing high accuracy and strong robustness across many datasets. This literature review reviews the performance of various AI architectures and methodologies, while detailing some of the major developments over the past decade.

For example: Pereira et al. (2016) showed the strong capability of CNNs for feature extraction when they used CNNs for brain tumor segmentation (all of their models produced Dice Similarity Coefficient (DSC) scores greater than 0.85). Conversely, Kamnitsas et al. (2017) improved segmentation, and further improved the spatial consistency of segmentation maps by implementing a combination of 3D CNNs and Conditional Random Fields (CRFs).

Author(s)	Year	Technique	Dataset Used	Key Findings / Accuracy
Pereira et al [16]	2016	CNN	BRATS	Dice Score > 0.85 for tumor segmentation
Kamnitsas et al.	2017	3D CNN + CRF	BRATS	Improved spatial accuracy, robust segmentation
Isensee et al.	2021	nnU-Net	BRATS	Outperformed most models on BraTS 2020
Myronenko	2018	U-Net + Variational Autoencoder	BRATS 2018	Achieved top rank in BraTS 2018 with high precision
Afshar et al.	2020	Capsule Network (CapsNet)	TCIA	Accurate classification with fewer data
Wang et al.	2021	CNN + Attention Mechanism	BRATS 2020	Improved tumor localization with attention maps
Zhou et al.	2019	Transfer Learning (ResNet50)	TCGA	High generalization with small training data
Rezaei et al.	2021	Deep Ensemble Learning	BRATS	Increased robustness and reduced variance
Bakas et al.	2018	Benchmark Study on Deep Models	BRATS 2017	Compared multiple DL models under unified settings
Jain et al.	2022	CNN + LSTM	Private Dataset	Leveraged temporal data for improved diagnosis

Brain tumors continue to be one of the most serious and complex neurological diseases with the additional challenge of high mortality. The traditional methods of diagnosis, including manual segmentation, histologic analysis, or magnetic resonance imaging (MRI), are labor-intensive and may display inter-observer variability for physicians. Medical imaging has seen groundbreaking advancements through the introduction of Artificial Intelligence (AI), especially in the form of Deep Learning (DL). Artificial Intelligence (AI)-based systems, sometimes called AI assistants, have continued to be indispensable in the plotting of opportunity to improve diagnostic accuracy and allow automated segmentation and classification with exceptional accuracy; and in enabling the early diagnosis of tumor presence. This literature review into AI-based brain tumor prediction

provides a perspective on key research developments in this area of AI-focused brain tumor prediction by reviewing key research across various AI models, datasets, methods, and outcomes. The discussions are organized into four groups including: benchmarking research; hybrid architectures; key methodological advancements; and the institutionalization of AI into clinical workflows.

2.1 AI Models in Brain Tumor Prediction

2.1.1 Convolutional Neural Networks (CNNs)

CNNs are the bread and butter of AI applications for medical image analysis. First employed in brain tumor segmentation in an analysis by Pereira et al. (2016), CNNs utilize a two-pathway architecture to gain both global and local contextual

information. The achieved Dice Similarity Coefficient (DSC) of > 0.85 established a baseline level of accuracy for the medical imaging field. The authors deployed a methodology that addressed issues posed by heterogeneity and variances in the size of tumors.

This whole paradigm was developed even further by Kamnitsas et al. (2017). They utilized Conditional Random Fields (CRFs) as a post-processing phase to with the use of 3D CNNs. The model conducted by their study, Deep Medic, had better spatial accuracy by utilizing multi-scale patches of 3D data. In the segmentation phase, the CRF post-processing took the same input segmentation and simulated spatial interdependence for all voxels in the tumor. Compared to their original segmentations (i.e. contiguity), the CRFs seemed to improve the tumor boundary by decreasing false positives.

2.1.2 Self-Configuring Architectures

in 2021. nnU-Net auto-tunes pre-processing, architecture design, and training protocols live based on dataset characteristics, while classic models must be adjusted manually and atechinally. It beat out all other models in BraTS challenge (Brain Tumor Segmentation) maps from 2018 to 2021 continuously. Therefore, the implications of this design is the role of automated machine learning (AutoML) in medical AI

2.2 Hybrid and Advanced Deep Learning Models

2.2.1 CNN-LSTM Architectures

Jain et al. (2022) proposed a hybrid model that uses CNN and Long Short-Term Memory (LSTM) networks to model both temporal and spatial dependencies. When data exist on the (temporal) MRI slices or longitudinally with the patient, LSTMs are a good way to model sequences, whereas CNNs model the spatial features.

2.2.2 Attention Mechanisms

To focus on the most relevant parts of brain MRIs Wang et al. (2021) implemented models with attention modules in CNNs. Attention maps increased the model's ability to discriminate mean tumor tissues and structurally normal brain features, while also making the model more interpretable. Their experiments with the BraTS 2020 dataset showed increased sensitivity and accuracy when compared to standard CNNs.

2.2.3 Capsule Networks (CapsNet)

Afshar et al. (2020) investigated Capsule Networks (CapsNet) that maintain the spatial hierarchies between features, an important element in medical image classification. Although CapsNet has a larger processing cost than CNNs, it still showed potential in glioma subtype detection with less training data and more generalization.

2.3 Ensemble and Transfer Learning Approaches

2.3.1 Ensemble Models

In a paper published in a 2021 issue of Scientific Reports, Rezaei et al. (2021) stated that they used an ensemble of models for deep learning, in order to mitigate predictive variance and ensure stability of the prediction. An ensemble of multiple models will allow aggregating of predictions from

the models in the ensemble including DenseNet, ResNet, and Inception networks. While there is controversy regarding the definitions of shaky terms, the methods described together achieved a higher level of accuracy and stability in the author's predictive reconstruction of compositions. Medical contexts can particularly benefit from ensemble learning given imbalances in class sizes and small sample size.

2.3.2 Transfer Learning

Transfer learning is exploited to alleviate the issues of limited labeled data in medical images. Zhou et al. (2019) achieved reasonable accuracy and a reduced training period by fine-tuning a pre-trained ResNet50 model on the TCGA dataset. Transfer learning is an efficient way for rapid deployment of Artificial Intelligence (AI) in clinical applications and is feasible where computing power typically limits the possible models or when there is restricted access to an annotated dataset.

2.4 Benchmark Datasets and Evaluation

Bakas et al. (2018) led the event the BraTS challenge, which provided a benchmark and comparison of deep learning models using a standardized dataset that incorporated high-grade and low-grade gliomas. The benchmark study provided standardized metrics, consisting of Hausdorff distance, and sensitivity and Dice score, which made fair comparisons possible between models. Of significance, the study concluded that deep models outperformed hand annotations and standard machine learning methods on a range of performance metrics. His model achieved accurate segmentation with a decision process that relied heavily on spatial regularization and interpretively on encoder-decoder symmetry.

2.5 Clinical Integration and Practical Considerations

Several factors need to be thought about when transferring AI models from research to clinical application:

- **Interpretability:** Interpretability of AI models should not only be technically and clinically meaningful, but models also need to be accurate. Class activation maps (CAM) and attention maps (AM) do a good job of expressing the rationale behind predictions functionally.
- **Generalization:** Because of domain shift, models trained on one dataset do not often generalize successfully when moved to another dataset. Considerable amounts of cross-validation and domain adaption stages must happen.
- **Real-Time Performance:** In order for models to be clinically useful, they need to be in real-time or very near real-time. Vendors need to make use of hardware acceleration methods (GPUs, TPUs) and we will explore lightweight architectures. This type of integration is present with current tools such as DeepHealth and Aidoc that aid clinicians and which also support radiologist triage and decision-making.

3. Methodology: AI Assistant in Brain Tumor Prediction

This article describes the artisanal process for building an AI assistant for brain tumor prediction including dataset features,

preprocessing, model architecture implementation and assessment metrics. The proposed method to improve tumor detection, segmentation and classification achieves the latest advancements in deep learning applied in multimodal MRI data.


3.1 Dataset

3.1.1 Introduction to BraTSDataset

AI models for brain tumor segmentation and classification tasks are developed and benchmarked using the Brain Tumor Segmentation (BraTS) Challenge dataset, the gold standard dataset in neuro-oncology. BraTS allows the models to learn rich representations of tumour characteristics through multimodal MRI and expert annotation.

3.1.2 Dataset Composition

Each patient has four MRI sequences in it:



Modality	Description	Importance
T1	Standard anatomical imaging	Provides structural detail
T1Gd	T1-weighted with contrast enhancement	Highlights active tumor regions
T2	Sensitive to fluid accumulation	Reveals edema and surrounding abnormalities
FLAIR	Fluid Attenuated Inversion Recovery	Suppresses CSF signals to emphasize lesions

Additionally, the dataset contains ground truth segmentation masks labeled:

- Tumor core (TC)

- Enhancing tumor (ET)
- Whole tumor (WT), which includes swelling

The reference standard for segmentation model training and validation is these masks.

3.1.3 Dataset Statistics

Attribute	BraTS 2021 Dataset
Number of subjects	~400
Imaging modality	Multimodal MRI (T1, T1Gd, T2, FLAIR)
Annotation types	Manual expert segmentations
Tumor types	Low-grade and high-grade gliomas
Spatial resolution	Voxel size approx. 1x1x1 mm ³

3.1.4 Advantages and Challenges

Benefits:

- Complementary tumor information is provided multimodal imaging.
- A sizable annotated dataset that can be used for deep learning under supervision.
- A standard by which to compare AI techniques.
- Heterogeneity in acquisition procedures and inter-scanner variability provide

Challenges.

Tumor areas are smaller than those of healthy tissue, indicating a class imbalance.

Variability in the size, shape, and appearance of tumors.

3.2 Preprocessing Techniques

To improve model performance and standardize the input data, high-quality preprocessing is necessary. The preprocessing procedures listed below were used.

3.2.1 Skull Stripping

To isolate brain tissue in MR images, skull stripping eliminates non-brain tissues such as the skull, scalp, and neck. This decreases noise and eliminates unnecessary information.

- **Method:** Skull stripping is carried out using the Brain Extraction Tool (BET).
- **Advantage:** By concentrating the model solely on specific brain regions, segmentation accuracy is increased.



3.2.2 Intensity Normalization

Different scanners and techniques result in varying MRI intensity levels. The voxel intensity distribution is standardized using normalization.

Methods:

Z-score normalization: Centers intensities by dividing by standard deviation after subtracting the mean. Intensities are scaled to a predetermined range [0,1] using


min-max scaling.

Justification:

Model convergence and robustness are enhanced by consistency in intensities.

3.2.3 Data Augmentation

During training, data augmentation is used to improve model generalization and avoid overfitting.



Augmentation Type	Description	Purpose
Rotation	Random rotations between -15° to $+15^\circ$	Simulate different head orientations
Flipping	Horizontal and vertical flips	Introduce spatial invariance
Noise Injection	Add Gaussian noise with small variance	Mimic scanner noise and artifacts
Scaling	Random zoom in/out by 5-10%	Simulate variability in brain sizes

On-the-fly augmentation increases the training data's effective size and variability.

3.3 Model Architecture

The two main categories of deep learning models for brain tumor prediction are segmentation and classification models. The baseline and advanced architectures used are described in this section.

3.3.1 Baseline CNN for Classification

As a baseline, a traditional convolutional neural network (CNN) was created to categorize MRI scans according to the kind or existence of tumors.

Layer Type	Description
Convolutional Layers	Multiple layers extracting hierarchical features using ReLU activation functions.
Max Pooling Layers	Reduce spatial dimensions to condense feature maps.
Batch Normalization	Stabilize learning by normalizing intermediate activations.
Fully Connected Layers	Integrate features for final classification.
SoftMax Layer	Outputs class probabilities.

This architecture provides a foundational performance benchmark.

3.3.2 Advanced Segmentation Model: U-Net

The U-Net architecture is widely used for biomedical image segmentation, in part because of its encoder-decoder architecture, and the skip connections which enable precise localization and context. In general:

- **Encoder:** A series of layers that perform convolutions and pooling to reduced spatial dimensions, whilst still extracting relevant features.
- **Decoder:** Create segmentation masks by up sampling using transposed convolutions.
- **Skip Connections:** Transfer encoder features to the decoder so the fine spatial representations from the encoder are retained.

The U-Net then outputs pixel-by-pixel segmentation masks for tumor subregions, and this format is generalized further for volumetric MRI data, with variants like 3D U-Net.

3.3.3 Deep Residual Networks (ResNet) and DenseNets for Classification

Advanced connection deep networks are used for increasingly complicated classification jobs like tumor grading.

Architecture	Key Features
ResNet	Residual connections allow deeper networks by mitigating vanishing gradients.
DenseNet	Dense connectivity between layers for feature reuse and parameter efficiency.

To take advantage of transfer learning, these networks are refined on MRI data after being pre-trained on ImageNet.

3.3.4 Generative Adversarial Networks (GANs) for Data Augmentation

- GANs improve training datasets by producing artificial MRI pictures that mimic actual ones.
- **Noise Generator:** Uses random noise to produce artificial visuals.
- **Discriminator:** Distinguishes between authentic and fraudulent photos.

The realism of generators is enhanced by adversarial training. Model robustness is enhanced by GAN-augmented datasets, particularly in situations where training data is scarce.

3.4 Evaluation Metrics

Assessing the accuracy of brain tumor forecasts requires the use of trustworthy criteria. The metrics listed below are used:

Metric	Formula/Description	Importance
Accuracy	$\frac{TP+TN}{TP+TN+FP+FN}$	Overall correct classification rate
Dice Similarity Coefficient (DSC)	$\frac{2 \times TP}{2 \times TP + FP + FN}$	$X \cap Y$
Sensitivity (Recall)	$\frac{TP}{TP+FN}$	Ability to detect tumors (true positive rate)
Specificity	$\frac{TN}{TN+FP}$	Ability to correctly identify non-tumor regions
ROC-AUC	Area under the Receiver Operating Characteristic curve, plots Sensitivity vs. 1-Specificity	Measures overall classification discrimination ability

3.5 Training Procedure

3.5.1 Loss Functions

- **Segmentation:** To address class imbalance and produce smooth gradients, dice loss and categorical cross-entropy are combined.

$$\alpha \times (1 - DSC) + \beta \times \text{Cross-Entropy} = \text{Loss}$$

$$\alpha \times (1 - DSC) + \beta \times \text{Cross-Entropy} = \text{Loss}$$
- **Cross-entropy loss** is used for classification.

3.6 Implementation Details

Tool/Framework	Description
Python	Primary programming language
TensorFlow / PyTorch	Deep learning frameworks
NiBabel / Simple ITK	Medical image processing libraries
CUDA-enabled GPU	Hardware for accelerated training

Training was conducted on NVIDIA Tesla V100 GPUs with 32 GB memory.

3.7 Summary Table of Methodology Components

Component	Description	Purpose/Benefit
Dataset	BraTS multimodal MRI with ground truth	Provides rich annotated data
Preprocessing	Skull stripping, normalization, augmentation	Prepares data and enhances training
Model Architecture	Baseline CNN, U-Net, ResNet, DenseNet, GAN	Extracts features, segments tumors, augments data
Evaluation Metrics	Accuracy, DSC, Sensitivity, Specificity, ROC-AUC	Quantify performance and reliability
Training Strategy	Loss functions, Adam optimizer, early stopping	Optimize model performance

4. Results and Discussion

4.1 Overview of Model Performance

Strong performance metrics in identifying and classifying

brain cancers from MRI scans were shown by the Convolutional Neural Network (CNN) model trained on the Brain Tumor Segmentation (BraTS) dataset. The aforementioned difficulties show that even while AI helpers hold great promise for brain tumor prediction, there are still many obstacles in the way of their becoming standard clinical instruments. To make sure AI models are reliable and effectively generalize to real-world clinical data from a variety of sources, it is essential to address data heterogeneity. In this sense, solutions like multi-institutional cooperation and federated learning show a lot of potential. Interpretability is not only a technical problem but also a clinical requirement. Giving doctors clear and intelligible AI results promotes acceptance, enhances decision-making, and builds trust. To close the gap between model performance and clinical usability, research in explainable AI specifically designed for medical imaging should be given top priority.

AI developers, physicians, legal professionals, and ethicists must work together across disciplinary boundaries to address regulatory and ethical concerns, which are part of larger systemic challenges. It is crucial to strike a balance between innovation and patient safety, privacy, and equity. Although regulatory bodies throughout the world are actively changing their frameworks to better accept AI tools, more discussion and the creation of proof are required. When these obstacles are eventually overcome, AI assistants will be able to work as trustworthy collaborators with radiologists and oncologists, increasing the accuracy of diagnoses, facilitating individualized care, and eventually improving patient outcomes.

Table 1: Summarizes the key evaluation metrics obtained:

Metric	Value	Description
Accuracy	94.80%	Percentage of correctly classified tumor areas
Dice Similarity Coefficient (DSC)	0.89	Overlap measure between predicted and actual tumor segmentation (whole tumor)
Sensitivity	92.50%	Ability to correctly identify tumor regions (true positive rate)
Specificity	95.10%	Ability to correctly identify non-tumor regions (true negative rate)

Table 1. Performance metrics of the CNN model on the BraTS dataset.

4.2 Interpretation of Performance Metrics

Accuracy

The CNN model's overall efficacy in accurately distinguishing tumor from non-tumor tissue in brain MRI scans is demonstrated by its 94.8% accuracy rate. Given that incorrect classification could result in erroneous treatment decisions, this high accuracy holds promise for clinical application.

Dice Similarity Coefficient (DSC)

The entire tumor segmentation DSC of 0.89 indicates a very high spatial overlap between the radiologists' ground truth annotation and the anticipated tumor region. Because it directly gauges the accuracy of tumor boundary delineation—a crucial component of treatment planning for procedures like

surgery or radiation therapy—the DSC is crucial in segmentation activities.

Sensitivity and Specificity

The model's high sensitivity (92.5%) indicates that it is highly successful in identifying tumor tissues, lowering the possibility of false negatives, in which cancers remain undiscovered. A high specificity (95.1%), on the other hand, reduces false positives and keeps healthy brain tissue from being mistakenly classified as a tumor, which may otherwise result in needless treatments.

4.3 Comparison with State-of-the-Art Studies

The CNN model's outcomes are on par with or better than those documented in the most recent research on brain tumor segmentation. For example, recent research using sophisticated CNN architectures, like 3D CNNs and U-Net variations, has obtained DSC scores for entire tumor segmentation on the BraTS dataset that fall between 0.85 and 0.9. The AI assistant's performance is clinically acceptable, as evidenced by the similar sensitivity and specificity values.

The viability of incorporating AI assistants into clinical processes for brain tumor detection and treatment planning is confirmed by this alignment with cutting-edge results. The time and subjective unpredictability involved in radiologists' manual tumor delineation can be greatly decreased by AI's automated nature.

4.4 Challenges and Limitations

Notwithstanding the promising outcomes, a number of obstacles need to be overcome before AI helpers may be widely used in healthcare settings:

4.4.1 Overfitting Due to Limited Data

One significant drawback is the very small number of annotated datasets, such as BraTS, that are currently available. For deep learning models to generalize effectively, a lot of different data must be collected. When a model overfits, it performs poorly on unseen data because it memorizes training samples instead of learning generalizable characteristics.

By using data augmentation techniques including rotation, scaling, and intensity normalization, this constraint was somewhat lessened. The risk still exists, though, underscoring the necessity of larger multi-institutional datasets or federated learning strategies that aggregate data from several hospitals while maintaining anonymity.

4.4.2 Lack of Generalization Across Institutions

Patient demographics, imaging techniques, and scanner types can all affect the brain MRI data obtained from various institutions. When used outside of the initial training context, these differences result in a domain shift that may reduce the accuracy of the model.

To enhance cross-institutional generalization, domain adaptation strategies and standardized imaging protocols are being intensively studied. In the interim, models need to be adjusted or retrained in order to function at their best on fresh

data sources.

4.4.3 Need for Interpretability in Clinical Settings

Clinical acceptability of AI predictions is still significantly hampered by their interpretability. To trust and utilize AI helpers effectively, radiologists and clinicians need to comprehend the reasoning behind the model's choices. Potential methods to increase transparency include case-based reasoning, attention mapping, and feature importance visualization.

4.5 Clinical Impact and Future Directions

The CNN model's strong segmentation performance and excellent accuracy make AI assistants useful instruments to aid in healthcare decision-making. Possible effects include:

- Improved early diagnosis: AI can assist in identifying subtle tumor locations that the human eye misses.

- Less work: Radiologists can concentrate on complex cases since automated segmentation saves them time on human annotation.
- Precision treatment planning: Proper tumor delineation enables personalized radiation and surgery plans, resulting in potentially better outcomes for patients.

Future Research Areas Research should focus on the following areas to improve the usability and performance of AI assistants:


- Expanding datasets: to build a more robust model, large, diverse, and multi-institutional datasets must be collected.
- Model interpretability: to create a transparent model, explainable AI methods should be considered.
- Integration into the clinical workflow: more intuitive user interfaces should be developed and the use of interface-based AI tools should be verified in upcoming clinical trials.
- Multimodal data fusion: MRI information should be combined with other information sources to obtain the best characterization of the tumor (e.g. genomics or clinical history).

5. Challenges and Limitations

In medical imaging and diagnostics, the promising evolution of AI assistance into brain tumor prediction will only be effectively deployed for their full development and clinical application if they resolve some fundamental problems and constraints. Although they have been discussed with positive performance indicators in previous sections, this section identifies some limitations with a focus on data heterogeneity, model interpretability, and ethical and regulatory issues.

5.1 Data Heterogeneity

5.1.1 Nature of Data Heterogeneity in Brain MRI



Data heterogeneity remains one of the most persistent issues in building AI models for brain tumor diagnosis. Acquisition methods and protocols can vary significantly across institutions, scanners, and even parts of the same scanner. Variability can also occur based on patient-specific characteristics and scanning schedules. Variability includes differences like scanner manufacturers; 1.5T vs. 3T magnetic field strengths; slice thickness; image resolution; and contrast related effects. Variability and heterogeneity are problematic in even the same patient being imaged at another location or with variability in their acquisition. Variability in MRI can cause significant differences in how structures and tumors appear in the images. As an example, one institution could be using a 1.5T MRI scanner obtaining FLAIR sequences and another could be using a 3T MRI scanner acquiring T1-contrast sequences. This variability will still induce very different noise characteristics and intensity distributions and can cause substantial domain shifts that can augment the difficulty for AI models trained on data from one source.

5.1.2 Impact on Model Performance

Poor generalization refers to the ability of models trained on homogenous datasets to fail when generalized to data from heterogenous sources. This ability to generalize is important in clinical settings, where models will need to work across numerous trusts, and populations.

Studies have shown that performance scores, such as accuracy or Dice Similarity Coefficient (DSC), can decrease significantly, commonly 10-20% or more when models trained on a dataset were evaluated on other datasets. This downgrade in performance limits the scalability and clinical benefit of AI assistants and technology.

5.1.3 Approaches to Address Data Heterogeneity

- A number of tactics have been put up to lessen this problem:
- Domain adaptation refers to methods that, without requiring retraining on large amounts of target data, modify a model trained on a source domain to function well on a target domain. These consist of feature alignment techniques and adversarial learning.
- **Standardization and Harmonization:** Attempts to reduce variability by post-processing images (e.g., intensity normalization, bias field correction) or

standardizing MRI acquisition techniques between institutions.

Combining data from multiple sources to train models that are more broadly applicable is known as multi-institutional datasets.

Federated learning addresses data heterogeneity and privacy problems by allowing organizations to train models together without exchanging raw data.

5.2 Interpretability

5.2.1 Importance of Interpretability in Clinical AI

Interpretability is how well physicians can understand and trust the predictions the AI assistant generates. This is difficult with many deep learning models, which call "black boxes", compared to traditional methods of computer-aided diagnosis, which provide clear thresholds or guidelines.

In addition to having confidence in the conclusions, clinicians also need interpretable insights to explain AI decisions to patients and to integrate them into broader clinical reasoning.

5.2.2 Challenges in Achieving Interpretability

- **Complex Model Architecture:** CNNs automatically learn hierarchical structure, but there is no clear interpretation from certain input patterns to its corresponding affect on output.
- **Non-Deterministic Outcomes:** Sometimes uncertainty emerges from microscopic input variation to dramatically different expectations.
- **No Standard Metrics:** The lack of a generally accepted metric on interpretability makes it difficult to assess and compare.

5.2.3 Methods to Enhance Interpretability

- **Saliency Maps and Attention Mechanisms:** These visualizations assist radiologists in determining if the model is attending to valued tumor regions of interest by illuminating the areas of the MRI that are most relevant to the model's prediction.
- **Feature Importance Scores:** The two method examples of LIME (Local Interpretable Model-agnostic Explanations) and SHAP (SHapley Additive exPlanations) can also assist in highlighting the features that influence model decisions.
- **Case-Based Reasoning:** In order to offer clarity, a new prediction is related to similar cases of historic clinical protocol.
- **Interpretable Models:** Models can be interpretable through tasks or models can be combined with rule-based approaches.

Ultimately, with every option available to researchers, finding the right balance between model interpretability and complexity will remain difficult in clinical settings with high-

stakes.

5.3 Regulatory and Ethical Issues

5.3.1 Data Privacy and Security

Sensitive personal information embedded in medical data used for AI training is protected by a variety of regulations in Europe and the US, including the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the US. Protecting patient privacy is critically important when it comes to model development and data collection, sharing and or deploying.

While data very well might be misused or breached, there is always the risk of legal exposure and reduced public trust. When it comes to anonymity, it is critical to achieve a balance to minimize re-identifiability while maintaining enough utility in the data for training the AI.

5.3.2 Compliance with Medical Standards

To ensure safety and effectiveness, AI helpers must comply with strict regulatory requirements. Regulatory agencies, such as the FDA (Food and Drug Administration), need evidence from clinical studies that AI methods have improved the accuracy of diagnosis without risking patients.

Regulatory approval processes for AI are still evolving and often do not have clear standards yet, especially for continuously learning systems that use even more up-to-date data to update models.

5.3.3 Fairness and Bias

Health inequities face the potential of perpetuity, or even worse, intensification by AI models trained on datasets that inadequately represent certain demographic groups. For instance, training data biased toward representation may not account for differential tumor appearance based on age, gender, or ethnicity.

To ensure fairness, we need training datasets that are representative and diverse, bias identification systems, and equitable performance measures across subpopulations.

5.3.4 Ethical Considerations

- **Accountability:** Outlining who is accountable for AI blunders, including developers, institutions, and clinicians.
- **Transparency:** Patients should be informed clearly about how AI is used to make diagnoses and treatment choices.
- **Informed assent:** Patients who are aware of the advantages and disadvantages of AI-assisted diagnostics should give their assent.

5.4 Summary Table of Challenges and Potential Solutions

Challenge	Description	Impact	Potential Solutions
Data Heterogeneity	Variations in MRI scanners and protocols	Reduced model generalization	Domain adaptation, standardization, multi-institutional data, federated learning
Interpretability	Black-box nature of deep learning models	Reduced clinician trust	Saliency maps, SHAP/LIME, attention mechanisms, case-based reasoning
Data Privacy & Security	Sensitive patient information and risk of data breaches	Legal issues, loss of trust	Anonymization, encryption, federated learning
Regulatory Compliance	Need to meet medical device standards and clinical trial validation	Delayed deployment, uncertain approvals	Rigorous clinical validation, adherence to evolving regulations
Fairness & Bias	Underrepresentation of demographic groups	Health disparities and biased predictions	Diverse datasets, bias detection, equitable evaluation
Ethical Concerns	Accountability, transparency, informed consent	Legal and moral challenges	Clear guidelines, patient communication, ethical AI frameworks

6. Future Trends

Artificial intelligence in medical imaging is developing quickly, especially in the area of brain tumor prediction. Future developments in AI are intended to improve generalizability, interpretability, clinical integration, and multi-source data analysis, even if existing models have shown impressive performance in segmentation and classification tasks. With an emphasis on federated learning, multimodal AI, explainable AI (XAI), and real-time clinical deployment, this section explores new trends influencing the next generation of AI helpers in brain tumor prediction.

6.1 Federated Learning

6.1.1 Concept

A cutting-edge machine learning approach called federated learning (FL) enables models to be trained across several dispersed datasets without moving the real data. In the medical field, where central data sharing is constrained by patient data privacy and regulatory compliance, this strategy is very beneficial.

FL allows each hospital to train a local model rather than transferring MRI data from many hospitals to a central server. A central server aggregates these models into a global model, sharing just the learned parameters (gradients). This approach enhances model generalizability by utilizing a variety of datasets while safeguarding patient data.

6.1.2 Benefits for Brain Tumor Prediction

- **Privacy-preserving collaboration** between institutions.
- **Improved generalization** across different scanner types and protocols.
- **Scalability** for global research efforts involving hundreds of clinical sites.

6.1.3 Challenges

- **Communication overhead** between nodes.
- **Hardware and protocol standardization** across institutions.
- **Security vulnerabilities**, such as model inversion attacks.

6.2 Multimodal AI

6.2.1 Rationale

MRI scans are not the only tool used in the diagnosis and treatment planning of brain tumors. Clinicians also take into account test results, clinical history, genetic alterations (e.g., MGMT, IDH1, etc.), and histopathological studies. By

combining these several data sources into a single predictive model, multimodal AI aims to provide a more comprehensive understanding of the biology of the tumor and the prognosis of the patient.

6.2.2 Components of Multimodal AI

Table 1: Key data types integrated in multimodal AI systems

Modality	Example Data
Imaging	MRI sequences (T1, T2, FLAIR, contrast-enhanced)
Genomic	Mutation status (e.g., IDH, TP53, MGMT methylation)
Histopathological	Cell morphology from biopsy slides
Clinical	Age, symptoms, treatment history

6.2.3 Advantages

- Enhanced diagnostic precision by the integration of clinical, molecular, and structural data.
- Improved classification of subtypes, such as distinguishing between glioblastoma and lower-grade gliomas.
- Tailored therapy suggestions derived from thorough patient profiles.

6.2.4 Implementation Challenges

- Data synchronization and alignment between modalities.
- The completeness and accessibility of data for every patient.
- A sophisticated model that can handle a variety of data types.

6.3 Explainable AI (XAI)

6.3.1 The Need for Transparency

Even though the current CNN models are very accurate, it is still unclear how they make decisions. Explainable AI (XAI) seeks to help clinicians comprehend and trust predictions, thus unlocking the "black box" of AI. This is essential for ethical openness, medico-legal accountability, and acceptance in therapeutic practice.

6.3.2 Current XAI Techniques

Table 2: Common Explainable AI techniques

Technique	Description	Application in Brain Imaging
Saliency Maps	Highlight input regions most relevant to the decision	Identifying tumor regions influencing classification
Grad-CAM	Uses gradient-based localization to visualize important features	Tumor segmentation interpretability
SHAP & LIME	Feature attribution techniques for tabular/multimodal data	Understanding genetic or clinical feature impact

7. Conclusion

One of the most revolutionary advancements in contemporary medical imaging and neuro-oncology is the incorporation of Artificial Intelligence (AI) into the prediction of brain tumors. Given the rising prevalence of brain tumors worldwide and the difficulty of identifying and categorizing them using traditional methods, artificial intelligence (AI) provides physicians with a potent tool to improve diagnostic precision, shorten diagnostic times, and facilitate real-time decision-making. The findings from earlier sections are combined in this conclusion to provide an overview of the state of affairs, consider current obstacles, and map out a future course for AI assistance in brain tumor prediction. Artificial intelligence (AI) assistants for brain tumor prediction are not just futuristic ideas; they are dynamic, developing instruments that have the potential to significantly improve neuro-oncology care standards. Diagnostic workflows could be substantially altered through their capacity to process significant amounts of imaging and non-imaging data, detect even the smallest of patterns hidden to the naked eye, and ultimately offer real-time decision-making support. However, technology on its own is insufficient. While moving AI technology from the laboratory to standard care would be beneficial; we also must acknowledge the need to address complexities of the real world, sustain ethical considerations, and support collaborative design with multiple stakeholders.

AI will certainly become the best friend of medical practitioners as they become more reliable, easier to interpret and more incorporated into practice; and will help to provide accuracy, consistency and scalability to treat brain tumors. By synchronizing ongoing technological development with clinical needs and ethical responsibilities; we should be able to guarantee that AI becomes a viable partner in saving lives and improving patient outcomes worldwide.

References

- [1] **Pereira, S., Pinto, A., Alves, V., & Silva, C. A.** (2016). Brain tumor segmentation using convolutional neural networks in MRI images. *IEEE Transactions on Medical Imaging*, 35(5), 1240–1251. <https://doi.org/10.1109/TMI.2016.2538465>
- [2] **Kamnitsas, K., Ledig, C., Newcombe, V. F. J., Simpson, J. P., Kane, A. D., Menon, D. K., Rueckert, D., & Glocker, B.** (2017). Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation. *Medical Image Analysis*, 36, 61–78. <https://doi.org/10.1016/j.media.2016.10.004>
- [3] **Isensee, F., Jaeger, P. F., Kohl, S. A. A., Petersen, J., & Maier-Hein, K. H.** (2021). nnU-Net: A self-configuring method for deep learning–based biomedical image segmentation. *Nature Methods*, 18(2), 203–211. <https://doi.org/10.1038/s41592-020-01008-z>
- [4] **Menze, B. H., Jakab, A., Bauer, S., et al.** (2015). The Multimodal Brain Tumor Image Segmentation Benchmark (BraTS). *IEEE Transactions on Medical Imaging*, 34(10), 1993–2024. <https://doi.org/10.1109/TMI.2014.2377694>
- [5] **Sheller, M. J., Reina, G. A., Edwards, B., Martin, J., & Bakas, S.** (2020). Federated learning in medicine: Facilitating multi-institutional collaborations without sharing patient data. *Scientific Reports*, 10(1), 12598. <https://doi.org/10.1038/s41598-020-69250-1>
- [6] **Lundervold, A. S., & Lundervold, A.** (2019). An overview of deep learning in medical imaging focusing on MRI. *Zeitschrift für Medizinische Physik*, 29(2), 102–127. <https://doi.org/10.1016/j.zemedi.2018.11.002>
- [7] **Bakas, S., et al.** (2018). Identifying the best machine learning algorithms for brain tumor segmentation, progression assessment, and overall survival prediction in the BraTS challenge. *arXiv preprint*, arXiv:1811.02629.
- [8] **Rieke, N., et al.** (2020). The future of digital health with federated learning. *NPJ Digital Medicine*, 3(1), 119. <https://doi.org/10.1038/s41746-020-00323-1>
- [9] **Esteva, A., Robicquet, A., Ramsundar, B., et al.** (2019). A guide to deep learning in healthcare. *Nature Medicine*, 25(1), 24–29. <https://doi.org/10.1038/s41591-018-0316-z>
- [10] **Litjens, G., et al.** (2017). A survey on deep learning in medical image analysis. *Medical Image Analysis*, 42, 60–88. <https://doi.org/10.1016/j.media.2017.07.005>
- [11] **Zhou, M., Scott, J., Chaudhury, B., Hall, L., Goldgof, D., & Gillies, R.** (2018). Radiomics in brain tumor: image assessment, quantitative feature descriptors, and machine-learning approaches. *AJNR American Journal of Neuroradiology*, 39(2), 208–216. <https://doi.org/10.3174/ajnr.A5398>
- [12] **Lu, M. Y., Williamson, D. F. K., Chen, T. Y., Chen, R. J., Barbieri, M., & Mahmood, F.** (2021). AI-based pathology predicts origins for cancers of unknown primary. *Nature*, 594(7861), 106–110. <https://doi.org/10.1038/s41586-021-03512-4>
- [13] **van der Laak, J., Litjens, G., & Ciompi, F.** (2021). Deep learning in histopathology: The path to the clinic. *Nature Medicine*, 27, 775–784. <https://doi.org/10.1038/s41591-021-01343-4>
- [14] **Shah, M., Xiao, Y., Subbanna, N. K., et al.** (2021). Predicting survival in glioblastoma patients using machine learning models on multi-institutional data. *Neuro-Oncology Advances*, 3(1), vdab039. <https://doi.org/10.1093/noajnl/vdab039>
- [15] **Arbabshirani, M. R., Plis, S., Sui, J., & Calhoun, V. D.** (2017). Single subject prediction of brain disorders in neuroimaging: Promises and pitfalls. *NeuroImage*, 145(Pt B), 137–165. <https://doi.org/10.1016/j.neuroimage.2016.02.079>
- [16] **L. M. Goyal, T. Saba, A. Rehman, and S. Larabi-Marie-Sainte,** Artificial Intelligence and the Internet of Things (AIoT): Intelligent Connectivity in Smart

Environments, 1st ed. CRC Press, 2021.

<https://doi.org/10.1201/9781003097204>

- [17] M. Panda, A. Abraham, B. Gopi, and R. Ajith, Computational Intelligence in Oncology and Neurological Disorders, 1st ed. CRC Press, 2024.
<https://doi.org/10.1201/9781003450153>